Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06628531

ALI & Pulmonary HA Deposition After SAH

Acute lung injury is a common complication of subarachnoid hematoma (SAH), and a significant risk factor for death in patients with SAH. Unlike neurogenic pulmonary edema and pneumonia following brain injury, the clinical causes of pulmonary injury after SAH are not intracranial hypertension or pulmonary infection. Its occurrence is influenced by the release of catecholamines, the regulatory function of the hypothalamic-pituitary-adrenal (HPA) axis and systemic inflammatory response, but the specific mechanisms are still unclear. Therefore, delving into the pathological mechanisms of SAH-induced lung injury and developing therapeutic strategies based on the findings is of great importance to improve the prognosis of patients.

Abnormal accumulation of hyaluronic acid in the lungs has been reported to be closely related to the pathological progression of various pulmonary injury diseases, such as chest trauma, pulmonary infection and chronic obstructive pulmonary disease. From this, the present research is aimed to explore the levels and dynamic changes of hyaluronic acid in the bronchoalveolar lavage fluid and blood of patients with acute lung injury following SAH, and to analyze its correlation with the prognosis of pulmonary complications, thereby providing assistance for the clinical diagnosis and treatment of SAH.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Subarachnoid Haemorrhage (SAH) Acute Lung Injury Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Hemorrhage Intracranial Hemorrhages Lung Diseases Lung Injury Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Subarachnoid Hemorrhage Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 80 years old with independent behavior ability or authorized legal representative.
  • A documented diagnosis of SAH within 5 days.
  • A Hunt-Hess scale of Ⅳ or Ⅴ.
  • Absence of clinical and etiological evidence of pulmonary infection.

Exclusion criteria

  • Pregnant or lactating women.
  • Present history of traumatic brain injury or intracranial hemorrhage.
  • Past history of neurological disorders, lung infection within the past six months, cancer, chronic cardiopulmonary diseases, hematological diseases or renal failure.
  • Have participated in clinical trials in the past 4 weeks.
  • The investigator considers that not appropriate for inclusion.

Treatment and study plan

Primary outcomes

  1. Hyaluronic acid level in bronchoalveolar lavage fluid after SAH

    Time frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

    Hyaluronic acid level (ng/ml) in bronchoalveolar lavage fluid at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

  2. Inflammatory cytokines levels in bronchoalveolar lavage fluid after SAH

    Time frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

    Inflammatory cytokines (IL-1β, TNF-α and IL-10) levels (pg/ml) in bronchoalveolar lavage fluid at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

Secondary outcomes

  1. Serum hyaluronic acid level after SAH

    Time frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

    Serum hyaluronic acid level (ng/ml) at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

  2. Serum inflammatory cytokines levels after SAH

    Time frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

    Serum inflammatory cytokines (IL-1β, TNF-α and IL-10) levels (pg/ml) at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

Study contacts

Contact information is provided by the study sponsor or research team.

Xintong Dr. Ge

CONTACT

[email protected]

86-13662055012

Sponsors and collaborators

Lead sponsor

Tianjin Medical University

Other

Registry information

Official study title

Relationship Between Acute Lung Injury and Pulmonary Hyaluronic Acid Deposition After Subarachnoid Hemorrhage

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Oct 8, 2024
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.